Monoclonal antibody-based optical molecular imaging probes; considerations and caveats in chemistry, biology and pharmacology.
The monoclonal antibody (mAb) has proven to be a good platform for designing specific molecular imaging probes due to its superior binding specificity. Several optical imaging probes have been developed for surgical navigation in patients and are in early phase clinical trials. However, an inherent limitation of using the mAb is its pharmacokinetics which result in a prolonged circulating half-life and slow clearance from the body. This results in undesirable target to background ratios during imaging. In this review, we first describe the mAb as a platform material for optical probe design and then discuss optimizing the design of monoclonal antibody-based optical molecular imaging probes by focusing on chemistry, biology and pharmacology.
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States. Electronic address: Kobayash@mail.nih.gov.
Hisataka
H
Kobayashi
Molecular Imaging Program, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, United States.
Peter L
PL
Choyke
Laboratory for Bioanalysis and Molecular Imaging, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo 060-0812, Japan.
Mikako
M
Ogawa
D000911:Antibodies, Monoclonal / Q000737:chemistry* / Q000493:pharmacokinetics; D005456:Fluorescent Dyes / Q000737:chemistry; D057054:Molecular Imaging / Q000379:methods*; D015335:Molecular Probes / Q000737:chemistry*
D000911:Antibodies, Monoclonal; D005456:Fluorescent Dyes; D015335:Molecular Probes